LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Diagnostic Assay Platform to Fasten Response Time to Emerging Pandemic Situations

By LabMedica International staff writers
Posted on 07 Feb 2023
Image: A collaborative project aims to deliver an innovative diagnostic platform for fast pandemic responsiveness (Photo courtesy of Clickmer)
Image: A collaborative project aims to deliver an innovative diagnostic platform for fast pandemic responsiveness (Photo courtesy of Clickmer)

The COVID-19 pandemic brought about a health crisis that highlighted severe fragilities within the healthcare sector, including lack of preparedness. In order to reduce vulnerability to future pandemics, there is a need for a large-scale, coordinated and comprehensive health response. Now, a new project aims to establish a diagnostic assay platform that can enable a faster response time during emerging pandemics.

A collaboration project, InfektoFlex, launched by Clickmer Systems (Manchester, UK) and Fraunhofer IMS (Duisburg, Germany) has received a EURO 1.1 million grant to develop an innovative diagnostic platform for fast pandemic responsiveness. The project which is due to commence in spring 2023 aims to establish a novel diagnostic assay platform that can enable a fast response time towards emerging pandemic situations. In the collaboration, Clickmers will be being combined with optical nanosensors, to develop a diagnostic assay platform with superior sensitivity and specificity having a faster response time for the detection of societal relevant emerging pathogens. Clickmers are synthetic antibody analogues that can bind to targets with high specificity and affinity. Optical nanosensors, which are fluorescent in near infrared light, qualify for low signal-to-noise ratio. Upon binding of a pathogen to the detection structure, the fluorescence of the nanosensor changes, thereby enabling measurement of the binding events.

“We are excited to launch the project InfektoFlex with Fraunhofer IMS. The platform will provide a more cost-efficient and time-saving solution, with a reduction in development costs through a more sustainable process compared to the commonly used ELISA assay systems (which require the usage of animal-derived antibodies),” said Dr. Ian Kavanagh, COO of APIS Assay Technologies. “Clickmer Systems will provide an adaptive and innovative diagnostic platform for pandemic responsiveness with higher reproducibility.”

Related Links:
Clickmer Systems 
Fraunhofer IMS 

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more